Premium
Complete remission of multiple myeloma after autoimmune hemolytic anemia: Possible association with interferon‐α
Author(s) -
Gesundheit Benjamin,
Zelig Orly,
Shapira Michael Y.,
Ackerstein Aliza,
Avgil Meytal,
Or Reuven
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20875
Subject(s) - autoimmune hemolytic anemia , multiple myeloma , medicine , hemolytic anemia , anemia , immunology , immunopathology , melphalan , bone marrow , autoimmune disease , immune system , antibody
A patient with multiple myeloma (MM) was being maintained on human recombinant interferon‐α (INF‐α) after VAD and autologous bone marrow transplantation (pretreated with melphalan). An episode of immune thrombocytopenia and (Coombs positive) autoimmune hemolytic anemia (AIHA) was noted while on maintenance INF‐α, which remitted when it was withdrawn. Following this event, he achieved a state of stable disease that persists (more than 3 years) with no specific myeloma treatment. This sequence of events suggests a relationship between an immunological reaction induced by INF‐α and the prolonged phase of stable disease. Am. J. Hematol., 2007. © 2007 Wiley‐Liss, Inc.